Fig. 5

Drug screen validation of key drugs worth investigation as first line or in combination with MAPKi in pLGG cells. a Summary dotplot depicting the results from a single-dose drug screen using n = 35 clinically relevant drugs targeting newly identified molecules and pathways in the senescent DKFZ-BT66 cells. Relative metabolic activity compared to the corresponding control is shown. The drug screen was performed in technical duplicates, and a single biological replicate. b Summary heatmap showing the IC₅₀ values (nM) of a given MAPK-dependent cytotoxic drug either used as a single agent or after a 24 h pre-treatment with 100 nM trametinib in senescent DKFZ-BT66 and senescent DKFZ-BT317 cells. The data depict the average IC₅₀ from n = 3 independent biological replicates. c Summary heatmap showing the IC₅₀ values (nM) of a given MAPK-(in)dependent cytotoxic drug in senescent or proliferating DKFZ-BT66 and DKFZ-BT317 cells. The data depict the average IC₅₀ from n = 3 independent biological replicates. * IC₅₀ taken from historical experiments conducted in the same conditions, published by Sigaud et al. for the DKFZ-BT66,²¹ and Selt et al. for the DKFZ-BT317.⁵³